Abstract
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by an excessive production of auto-antibodies against double-stranded DNA, nucleosomes, ribonucleoproteins and other nuclear components. Accumulation of self-reactive antibodies leads to immune complex deposition in blood vessels, activation of macrophages and complement, inflammation and subsequent tissue damage in several organs, such as the heart, kidneys, lungs and central nervous system. Although significant progress has been made in the past 30 years of research, no effective specific treatments are currently available. The course of this disease remains unpredictable and patients diagnosed with SLE face long-term treatments with the subsequent economic, social and health burden. From the immunological perspective, SLE is a genetic- and environment-controlled disease that involves almost every constituent of the immune system, including both innate and adaptive immunity. Therefore, several immune cell types and molecules could be susceptible for intervention and modulation to develop more effective and specific treatments. More importantly, such therapies are likely not to induce complete immunosuppression and show reduced side effects on patients. In this article we discuss recent work in the field of SLE pathogenesis with a focus on data that provide clues for therapy design and new treatments.
Keywords: Autoimmune diseases, dendritic cells, immune tolerance, immunotherapy, lupus, T cells
Current Gene Therapy
Title: Genetic and Pharmacological Modulation of Dendritic Cell-T Cell Interactions as a Therapeutic Strategy for Systemic Lupus Erythematosus
Volume: 11 Issue: 6
Author(s): Carolina Llanos, Leandro J. Carreno, Miguel A. Gutierrez, Claudia A. Riedel, Sergio H. Jacobelli and Alexis M. Kalergis
Affiliation:
Keywords: Autoimmune diseases, dendritic cells, immune tolerance, immunotherapy, lupus, T cells
Abstract: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by an excessive production of auto-antibodies against double-stranded DNA, nucleosomes, ribonucleoproteins and other nuclear components. Accumulation of self-reactive antibodies leads to immune complex deposition in blood vessels, activation of macrophages and complement, inflammation and subsequent tissue damage in several organs, such as the heart, kidneys, lungs and central nervous system. Although significant progress has been made in the past 30 years of research, no effective specific treatments are currently available. The course of this disease remains unpredictable and patients diagnosed with SLE face long-term treatments with the subsequent economic, social and health burden. From the immunological perspective, SLE is a genetic- and environment-controlled disease that involves almost every constituent of the immune system, including both innate and adaptive immunity. Therefore, several immune cell types and molecules could be susceptible for intervention and modulation to develop more effective and specific treatments. More importantly, such therapies are likely not to induce complete immunosuppression and show reduced side effects on patients. In this article we discuss recent work in the field of SLE pathogenesis with a focus on data that provide clues for therapy design and new treatments.
Export Options
About this article
Cite this article as:
Llanos Carolina, J. Carreno Leandro, A. Gutierrez Miguel, A. Riedel Claudia, H. Jacobelli Sergio and M. Kalergis Alexis, Genetic and Pharmacological Modulation of Dendritic Cell-T Cell Interactions as a Therapeutic Strategy for Systemic Lupus Erythematosus, Current Gene Therapy 2011; 11 (6) . https://dx.doi.org/10.2174/156652311798192806
DOI https://dx.doi.org/10.2174/156652311798192806 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Expression Profiles in Human Autoimmune Disease
Current Pharmaceutical Design Immunogenicity in Protein and Peptide Based-Therapeutics: An Overview
Current Protein & Peptide Science Metformin - The Drug for the Treatment of Autoimmune Diseases; A New Use of a Known Anti-Diabetic Drug
Current Topics in Medicinal Chemistry Epigenetic Regulation of Regulatory T Cells in Kidney Disease and Transplantation
Current Gene Therapy Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design The Dendritic Cell-T Cell Synapse as a Determinant of Autoimmune Pathogenesis
Current Pharmaceutical Design Autoimmune Diseases in Gastroenterology
Current Pharmaceutical Design Immunomodulatory Role of Arsenic in Regulatory T Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets The Potential of Selected Prostanoid Receptors as Targets in a New Therapeutic Strategy for Allergy and Immune Diseases
Current Drug Safety B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design B Cell Depletion with Rituximab in Graves Disease and Associated Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmunity in Type 1 Diabetes
Current Stem Cell Research & Therapy The Use of Mesenchymal Stem Cells for the Treatment of Autoimmunity: From Animals Models to Human Disease
Current Drug Targets Natural and Induced Regulatory T Cells: Targets for Immunotherapy of Autoimmune Disease and Allergy
Inflammation & Allergy - Drug Targets (Discontinued) Comparative Molecular Characterization to Reveal Surface Behaviour of Non-proteolytic Bromelain Mutants
Current Pharmaceutical Biotechnology Recent Advances for Cell / Gene Therapy in Rheumatoid Arthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Impact of Fc Receptors on the Development of Autoimmune Diseases
Current Pharmaceutical Design Inhibitor at the Gates, Inhibitor in the Chamber: Allosteric and Competitive Inhibitors of the Proteasome as Prospective Drugs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents HSP60 is a Ubiquitous Player in the Physiological and Pathogenic Interactions between the Chaperoning and the Immune Systems
Current Immunology Reviews (Discontinued) Nanotechnology in Therapeutics – Current Technologies and Applications
Current Nanoscience